KMT2E
Basic information
Region (hg38): 7:104940943-105115019
Previous symbols: [ "MLL5" ]
Links
Phenotypes
GenCC
Source:
- intellectual disability, autosomal dominant 40 (Definitive), mode of inheritance: AD
- O'Donnell-Luria-Rodan syndrome (Moderate), mode of inheritance: AD
- O'Donnell-Luria-Rodan syndrome (Strong), mode of inheritance: AD
- syndromic intellectual disability (Supportive), mode of inheritance: AD
- O'Donnell-Luria-Rodan syndrome (Strong), mode of inheritance: AD
- complex neurodevelopmental disorder (Definitive), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
O'Donnell-Luria-Rodan syndrome | AD | Cardiovascular | The condition can involve congenital cardiac anomalies, and awareness may allow early management | Cardiovascular; Craniofacial; Gastrointestinal; Genitourinary; Musculoskeletal; Neurologic | 31079897 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (20 variants)
- O'Donnell-Luria-Rodan syndrome (16 variants)
- Inborn genetic diseases (6 variants)
- Intellectual disability (1 variants)
- Neurodevelopmental disorder (1 variants)
- Neurodevelopmental delay (1 variants)
- See cases (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the KMT2E gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 147 | 15 | 164 | |||
missense | 362 | 36 | 41 | 445 | ||
nonsense | 13 | 13 | 28 | |||
start loss | 0 | |||||
frameshift | 29 | 22 | 17 | 68 | ||
inframe indel | 22 | 28 | ||||
splice donor/acceptor (+/-2bp) | 9 | |||||
splice region | 2 | 9 | 17 | 5 | 33 | |
non coding | 54 | 13 | 74 | |||
Total | 42 | 50 | 411 | 243 | 70 |
Variants in KMT2E
This is a list of pathogenic ClinVar variants found in the KMT2E region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
7-105040858-A-G | Uncertain significance (Feb 27, 2023) | |||
7-105040965-A-T | O'Donnell-Luria-Rodan syndrome | Uncertain significance (Aug 15, 2023) | ||
7-105040966-T-A | O'Donnell-Luria-Rodan syndrome | Uncertain significance (Nov 04, 2022) | ||
7-105040970-A-G | Likely benign (Jun 20, 2022) | |||
7-105040971-T-C | Likely benign (Mar 24, 2023) | |||
7-105040973-G-A | KMT2E-related disorder | Likely benign (Dec 17, 2023) | ||
7-105040984-C-T | Uncertain significance (Aug 02, 2023) | |||
7-105040994-G-A | KMT2E-related disorder | Benign (Jan 04, 2024) | ||
7-105041005-A-G | Uncertain significance (Aug 13, 2019) | |||
7-105041015-AG-A | O'Donnell-Luria-Rodan syndrome | Likely pathogenic (Apr 28, 2021) | ||
7-105041020-C-T | Uncertain significance (Jun 07, 2023) | |||
7-105041042-TA-T | Likely benign (Dec 26, 2023) | |||
7-105062147-C-G | Benign (Feb 01, 2024) | |||
7-105062155-T-TC | KMT2E-related disorder | Benign (Apr 05, 2022) | ||
7-105062156-C-T | Benign/Likely benign (Dec 14, 2023) | |||
7-105062167-A-G | Benign/Likely benign (Mar 01, 2024) | |||
7-105062173-C-T | Likely benign (Aug 22, 2023) | |||
7-105062174-G-A | Uncertain significance (Jul 28, 2023) | |||
7-105062191-G-C | Likely benign (May 31, 2023) | |||
7-105062196-T-C | Benign (Dec 06, 2023) | |||
7-105062198-G-C | Uncertain significance (Jun 05, 2024) | |||
7-105062228-T-C | Uncertain significance (Oct 15, 2023) | |||
7-105062234-A-G | KMT2E-related disorder | Uncertain significance (Dec 16, 2023) | ||
7-105062239-C-T | Likely benign (Jan 16, 2022) | |||
7-105062258-TA-T | See cases | Uncertain significance (Feb 07, 2019) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
KMT2E | protein_coding | protein_coding | ENST00000311117 | 25 | 100183 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.00 | 1.59e-12 | 125706 | 0 | 39 | 125745 | 0.000155 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.42 | 849 | 974 | 0.872 | 0.0000500 | 12103 |
Missense in Polyphen | 39 | 47.469 | 0.82158 | 441 | ||
Synonymous | -2.60 | 410 | 348 | 1.18 | 0.0000186 | 3673 |
Loss of Function | 8.11 | 1 | 78.6 | 0.0127 | 0.00000376 | 1044 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000383 | 0.000359 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000285 | 0.000272 |
Finnish | 0.0000958 | 0.0000924 |
European (Non-Finnish) | 0.000156 | 0.000149 |
Middle Eastern | 0.000285 | 0.000272 |
South Asian | 0.000298 | 0.000294 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Associates with chromatin regions downstream of transcriptional start sites of active genes and thus regulates gene transcription (PubMed:23629655, PubMed:24130829, PubMed:23798402). Chromatin interaction is mediated via the binding to tri-methylated histone H3 at 'Lys-4' (H3K4me3) (PubMed:24130829, PubMed:23798402). Key regulator of hematopoiesis involved in terminal myeloid differentiation and in the regulation of hematopoietic stem cell (HSCs) self-renewal by a mechanism that involves DNA methylation (By similarity). Also acts as an important cell cycle regulator, participating in cell cycle regulatory network machinery at multiple cell cycle stages including G1/S transition, S phase progression and mitotic entry (PubMed:14718661, PubMed:18573682, PubMed:19264965, PubMed:23629655). Recruited to E2F1 responsive promoters by HCFC1 where it stimulates tri-methylation of histone H3 at 'Lys-4' and transcriptional activation and thereby facilitates G1 to S phase transition (PubMed:23629655). During myoblast differentiation, required to suppress inappropriate expression of S-phase-promoting genes and maintain expression of determination genes in quiescent cells (By similarity). {ECO:0000250|UniProtKB:Q3UG20, ECO:0000269|PubMed:14718661, ECO:0000269|PubMed:18573682, ECO:0000269|PubMed:23629655, ECO:0000269|PubMed:23798402, ECO:0000269|PubMed:24130829}.;
- Pathway
- Lysine degradation - Homo sapiens (human);Histone Modifications;Gene expression (Transcription);Generic Transcription Pathway;PKMTs methylate histone lysines;RNA Polymerase II Transcription;RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function;Chromatin modifying enzymes;Glycosphingolipid metabolism;Chromatin organization;Transcriptional regulation by RUNX1
(Consensus)
Recessive Scores
- pRec
- 0.114
Intolerance Scores
- loftool
- rvis_EVS
- -1.45
- rvis_percentile_EVS
- 3.9
Haploinsufficiency Scores
- pHI
- 0.431
- hipred
- Y
- hipred_score
- 0.613
- ghis
- 0.622
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- gene_indispensability_score
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Kmt2e
- Phenotype
- adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); endocrine/exocrine gland phenotype; growth/size/body region phenotype; cellular phenotype; immune system phenotype; homeostasis/metabolism phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; hematopoietic system phenotype; vision/eye phenotype;
Gene ontology
- Biological process
- neutrophil mediated immunity;DNA methylation;cell cycle arrest;erythrocyte differentiation;histone lysine methylation;neutrophil activation;regulation of megakaryocyte differentiation;positive regulation of transcription, DNA-templated;positive regulation of G1/S transition of mitotic cell cycle;positive regulation of histone H3-K4 trimethylation
- Cellular component
- chromatin;nucleus;nucleoplasm;cytoplasm;microtubule organizing center;plasma membrane;nuclear speck;protein-containing complex;transcriptionally active chromatin
- Molecular function
- protein binding;histone-lysine N-methyltransferase activity;enzyme binding;methylated histone binding;metal ion binding